Palatrigine (also known as BW A256C) was developed and classified as a novel "slow" class 1C antiarrhythmic agent. Information about the current use of this drug is not available.

Droxacin is quinolone antibiotic. It is topoisomerase inhibitor.

Teflurane was first used in man in 1960. A series of thirty anesthetics completed in the first six months suggested that the teflurane was essentially non-toxic to the circulatory system and to hepatic and renal function. However, when the drug was given at inspired concentrations of 10 % and above, cardiac arrhythmias appeared, increased in severity and significance and systolic and diastolic blood pressures fell in direct proportion to the concentration given. That is why the further development of the teflurane was terminated.

Rimcazole is a carbazole derivative that acts as a sigma receptor antagonist and studied as potential antipsychotic agent for the treatment of acute schizophrenic patients. In open-clinical trials Rimcazole (BW 234U) appears to be effective in acute schizophrenic patients. However, subsequent clinical trials demonstrated that rimcazole lacked efficacy in schizophrenic patients and it is now primarily used as an experimental tool. In addition to its actions as  receptor antagonist, rimcazole also has high affinity for dopamine transporters, and inrecent years it has served as a lead compound for the development of novel dopamine transporter ligands.

Paraxazone is a monoamine oxidase Inhibitor that was studied as an antidepressant but has never been marketed. Information about the current use of this drug is not available.

LAROTAXEL is a taxoid with potential antineoplastic activity. It prevents microtubule depolymerization, thereby inhibiting cell proliferation. It displays a broad spectrum of antitumor activity in vitro and in vivo, including activity against P-glycoprotein expressing tumors. LAROTAXEL was in phase III clinical trials for the treatment of breast cancer, pancreatic cancer, and bladder cancer. However, its development was discontinued.

SITOGLUSIDE (Daucosterol) inhibits cancer cell proliferation by inducing autophagy through reactive oxygen species-dependent manner. It also perturbs cell cycle and induces apoptotic cell death in A549 cells. Daucosterol has being shown to promote the proliferation of neural stem cells. Daucosterol also protects neurons against oxygen-glucose deprivation/reperfusion-mediated injury by activating IGF1 signaling pathway. Daucosterol could be potentially developed as a medicine for ischemic stroke treatment.